Dan Ross, MBA

RemeGen
San Diego, CA, United States

Dan Ross is a member of the senior management team of RemeGen. He has worked closely with the company and its investigators in support of RC18 Telitacicept clinical development since 2017.

Disclosure information not submitted.

Presentation(s):

• L07: Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study

  Monday, November 14, 2022
  1:00 PM – 3:00 PM Eastern Time

• L07: Telitacicept, a Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Systemic Lupus Erythematosus (SLE): Results of a Phase 3 Study

  Monday, November 14, 2022
  2:00 PM – 2:05 PM Eastern Time